Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II DJ-927 monotherapy every 3 weeks in second-line NSCLC
2004-000696-34Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exatecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall tumor response. Started Jul 2004; status: completed.
02
Drugs
exatecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000696-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000696-34.